Decreased plasma concentrations of BDNF and IGF-1 in abstinent patients with alcohol use disorders

PLoS One. 2017 Nov 6;12(11):e0187634. doi: 10.1371/journal.pone.0187634. eCollection 2017.

Abstract

The identification of growth factors as potential biomarkers in alcohol addiction may help to understand underlying mechanisms associated with the pathogenesis of alcohol use disorders (AUDs). Previous studies have linked growth factors to neural plasticity in neurocognitive impairment and mental disorders. In order to further clarify the impact of chronic alcohol consumption on circulating growth factors, a cross-sectional study was performed in abstinent AUD patients (alcohol group, N = 91) and healthy control subjects (control group, N = 55) to examine plasma concentrations of brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1) and IGF-1 binding protein-3 (IGFBP-3). The association of these plasma peptides with relevant AUD-related variables and psychiatric comorbidity was explored. The alcohol group was diagnosed with severe AUD and showed an average of 13 years of problematic use and 10 months of abstinence at the moment of participating in the study. Regarding common medical conditions associated with AUD, we observed an elevated incidence of alcohol-induced liver and pancreas diseases (18.7%) and psychiatric comorbidity (76.9%). Thus, AUD patients displayed a high prevalence of dual diagnosis (39.3%) [mainly depression (19.9%)] and comorbid substance use disorders (40.7%). Plasma BDNF and IGF-1 concentrations were significantly lower in the alcohol group than in the control group (p<0.001). Remarkably, there was a negative association between IGF-1 concentrations and age in the control group (r = -0.52, p<0.001) that was not found in the alcohol group. Concerning AUD-related variables, AUD patients with liver and pancreas diseases showed even lower concentrations of BDNF (p<0.05). In contrast, the changes in plasma concentrations of these peptides were not associated with abstinence, problematic use, AUD severity or lifetime psychiatric comorbidity. These results suggest that further research is necessary to elucidate the role of BDNF in alcohol-induced toxicity and the biological significance of the lack of correlation between age and plasma IGF-1 levels in abstinent AUD patients.

MeSH terms

  • Adult
  • Alcohol-Related Disorders / blood*
  • Biomarkers / blood
  • Brain-Derived Neurotrophic Factor / blood*
  • Case-Control Studies
  • Cross-Sectional Studies
  • Female
  • Humans
  • Insulin-Like Growth Factor Binding Protein 3 / blood
  • Insulin-Like Growth Factor I / metabolism*
  • Male
  • Middle Aged
  • Substance Withdrawal Syndrome / blood*

Substances

  • Biomarkers
  • Brain-Derived Neurotrophic Factor
  • Insulin-Like Growth Factor Binding Protein 3
  • Insulin-Like Growth Factor I
  • BDNF protein, human

Grants and funding

The present study has been supported by RETICS Red de Trastornos Adictivos (RD16/0017/0001) funded by Instituto de Salud Carlos III (ISC-III) and European Regional Development Funds-European Union (ERDF-EU); Research project funded by Ministerio de Economía y Competitividad and ISC-III (PI13/02261, PI16/01698 and PI16/01953); Research project funded by Ministerio de Sanidad, Servicios Sociales e Igualdad and Plan Nacional sobre Drogas (PNSD 049/2013); Research project funded by Consejería de Economía, Innovación y Ciencia, Junta de Andalucía and ERDF-EU (CTS-433); Research projects funded by Consejería de Salud y Bienestar Social, Junta Andalucía (PI0228-2013). JS, AS and FJP hold Miguel Servet research contracts funded by ISC-III and ERDF-EU (CP12/03109, CP14/00173 and CP14/00212, respectively). EC-O holds a “Sara Borrell” research contract funded by ISC-III and ERDF-EU (CD12/00455).